QUASAR LTE study
Johnson & Johnson Reports Long‑Term TREMFYA Data: 80% in Remission
Johnson & Johnson (NYSE:JNJ) has announced new long‑term data from the QUASAR LTE study, showing that TREMFYA® (guselkumab) sustained clinical, endoscopic, and histologic outcomes through Week 140 in adults with moderately to severely active ulcerative colitis. More than 80% of patients were in clinical remission, over 50% achieved endoscopic remission, and nearly 79% showed histo‑endoscopic…
